SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP Heart Failure Long-Term Registry.

Kapłon-Cieślicka, A; Benson, L; Chioncel, O; Crespo-Leiro, MG; Coats, AJS; Anker, SD; Ruschitzka, F; Hage, C; Drożdż, J; Seferovic, P; et al. Kapłon-Cieślicka, A; Benson, L; Chioncel, O; Crespo-Leiro, MG; Coats, AJS; Anker, SD; Ruschitzka, F; Hage, C; Drożdż, J; Seferovic, P; Rosano, GMC; Piepoli, M; Mebazaa, A; McDonagh, T; Lainscak, M; Savarese, G; Ferrari, R; Mullens, W; Bayes-Genis, A; Maggioni, AP; Lund, LH; on behalf of the Heart Failure Association (HFA) of the European (2023) Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail, 25 (9). pp. 1571-1583. ISSN 1879-0844 https://doi.org/10.1002/ejhf.2873
SGUL Authors: Rosano, Giuseppe Massimo Claudio

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (981kB) | Preview
[img] Archive (ZIP) (Appendix S1. Supporting Information) Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (97kB)

Abstract

AIMS: To comprehensively assess hyponatraemia in acute heart failure (AHF) regarding prevalence, associations, hospital course, and post-discharge outcomes. METHODS AND RESULTS: Of 8298 patients in the European Society of Cardiology Heart Failure Long-Term Registry hospitalized for AHF with any ejection fraction, 20% presented with hyponatraemia (serum sodium <135 mmol/L). Independent predictors included lower systolic blood pressure, estimated glomerular filtration rate (eGFR) and haemoglobin, along with diabetes, hepatic disease, use of thiazide diuretics, mineralocorticoid receptor antagonists, digoxin, higher doses of loop diuretics, and non-use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers. In-hospital death occurred in 3.3%. The prevalence of hyponatraemia and in-hospital mortality with different combinations were: 9% hyponatraemia both at admission and discharge (hyponatraemia Yes/Yes, in-hospital mortality 6.9%), 11% Yes/No (in-hospital mortality 4.9%), 8% No/Yes (in-hospital mortality 4.7%), and 72% No/No (in-hospital mortality 2.4%). Correction of hyponatraemia was associated with improvement in eGFR. In-hospital development of hyponatraemia was associated with greater diuretic use and worsening eGFR but also more effective decongestion. Among hospital survivors, 12-month mortality was 19% and adjusted hazard ratios (95% confidence intervals) were for hyponatraemia Yes/Yes 1.60 (1.35-1.89), Yes/No 1.35 (1.14-1.59), and No/Yes 1.18 (0.96-1.45). For death or heart failure hospitalization they were 1.38 (1.21-1.58), 1.17 (1.02-1.33), and 1.09 (0.93-1.27), respectively. CONCLUSION: Among patients with AHF, 20% had hyponatraemia at admission, which was associated with more advanced heart failure and normalized in half of patients during hospitalization. Admission hyponatraemia (possibly dilutional), especially if it did not resolve, was associated with worse in-hospital and post-discharge outcomes. Hyponatraemia developing during hospitalization (possibly depletional) was associated with lower risk.

Item Type: Article
Additional Information: © 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Keywords: Acute heart failure, Congestion, Hyponatraemia, Prognosis, Sodium, Worsening heart failure, Acute heart failure, Worsening heart failure, Hyponatraemia, Sodium, Prognosis, Congestion, 1102 Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur J Heart Fail
ISSN: 1879-0844
Language: eng
Dates:
DateEvent
17 October 2023Published
23 May 2023Published Online
23 April 2023Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDAbbott Vascular Int.UNSPECIFIED
UNSPECIFIEDAmgen CardiovascularUNSPECIFIED
UNSPECIFIEDAstraZenecahttp://dx.doi.org/10.13039/100004325
UNSPECIFIEDBayer AGUNSPECIFIED
UNSPECIFIEDBoehringer Ingelheimhttp://dx.doi.org/10.13039/100001003
UNSPECIFIEDBoston ScientificUNSPECIFIED
UNSPECIFIEDDaiichi Sankyo Europehttp://dx.doi.org/10.13039/501100022274
UNSPECIFIEDEdwardsUNSPECIFIED
UNSPECIFIEDGedeon Richter Plc.UNSPECIFIED
UNSPECIFIEDMenarini Int. OpUNSPECIFIED
UNSPECIFIEDMSD-Merck & Co.UNSPECIFIED
UNSPECIFIEDNovartis Pharma AGUNSPECIFIED
UNSPECIFIEDResMedhttp://dx.doi.org/10.13039/100017647
UNSPECIFIEDSanofihttp://dx.doi.org/10.13039/100004339
UNSPECIFIEDServierhttp://dx.doi.org/10.13039/501100011725
UNSPECIFIEDThe Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and CompanyUNSPECIFIED
UNSPECIFIEDThe Bristol Myers Squibb and Pfizer AllianceUNSPECIFIED
UNSPECIFIEDViforUNSPECIFIED
PubMed ID: 37114294
Web of Science ID: WOS:000993762100001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115535
Publisher's version: https://doi.org/10.1002/ejhf.2873

Actions (login required)

Edit Item Edit Item